A164060 Stock Overview
Researches, develops, manufactures, and sells medical devices in South Korea and internationally.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Ilooda Co., Ltd Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩7,090.00 |
52 Week High | ₩8,440.00 |
52 Week Low | ₩4,995.00 |
Beta | 0.27 |
11 Month Change | 4.88% |
3 Month Change | 5.19% |
1 Year Change | -4.06% |
33 Year Change | 38.65% |
5 Year Change | n/a |
Change since IPO | 2.62% |
Recent News & Updates
Shareholder Returns
A164060 | KR Medical Equipment | KR Market | |
---|---|---|---|
7D | 0% | -0.2% | 1.4% |
1Y | -4.1% | 24.4% | 2.8% |
Return vs Industry: A164060 underperformed the KR Medical Equipment industry which returned 25.7% over the past year.
Return vs Market: A164060 underperformed the KR Market which returned 4.7% over the past year.
Price Volatility
A164060 volatility | |
---|---|
A164060 Average Weekly Movement | 6.7% |
Medical Equipment Industry Average Movement | 8.1% |
Market Average Movement | 6.8% |
10% most volatile stocks in KR Market | 12.1% |
10% least volatile stocks in KR Market | 3.5% |
Stable Share Price: A164060 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A164060's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2006 | 102 | n/a | ilooda.com |
Ilooda Co., Ltd researches, develops, manufactures, and sells medical devices in South Korea and internationally. The company offers aesthetic products under the reepot, curas hybrid, n.core 3D, n.core PRIME, hyzer me, Secret RF, Secret DUO, FRAXIS DUO, VIKINI, VELOCE, curas, PENTO, Healer 1064, and Ultra Beaujet; and ophthalmic products under the ACUTRON and RetiCapture. Its products are used in skin resurfacing and rejuvenation, scar treatment, tattoo removal, vascular, and pigmented lesions.
Ilooda Co., Ltd Fundamentals Summary
A164060 fundamental statistics | |
---|---|
Market cap | ₩148.70b |
Earnings (TTM) | -₩6.75b |
Revenue (TTM) | ₩57.00b |
2.6x
P/S Ratio-22.0x
P/E RatioIs A164060 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A164060 income statement (TTM) | |
---|---|
Revenue | ₩57.00b |
Cost of Revenue | ₩25.48b |
Gross Profit | ₩31.52b |
Other Expenses | ₩38.26b |
Earnings | -₩6.75b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -321.65 |
Gross Margin | 55.29% |
Net Profit Margin | -11.84% |
Debt/Equity Ratio | 53.6% |
How did A164060 perform over the long term?
See historical performance and comparison